Alembic Pharmaceuticals Ltd has received final approval from the US Food and Drug Administration for prazosin hydrochloride capsules USP in 1 mg, 2 mg, and 5 mg strengths, the company said in an exchange filing.
The drug is a generic version of Pfizer Inc's Minipress capsules.
It is indicated for the treatment of hypertension to lower blood pressure.
According to data by IQVIA, the drug had sales of approximately $50 mln for the 12-month period ended December.
Shares of the company traded 0.8% lower at ₹521.05 on the NSE, at 09:15 IST.
